Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 domain binding kinase family member 2 (SBK2)
- Target
- SBK2
- Molecular classification
- Enzyme (kinase), Serine/threonine protein kinase, Predicted MAP kinase kinase activity (GO annotation, molecular evidence)
01
Overview
SBK2 encodes an evolutionarily conserved putative serine/threonine protein kinase with muscle-specific, highly atrium-enriched expression, particularly localized around the A-band of cardiac sarcomeres[7]. It is predicted to function in the MAP kinase cascade and may have roles in signal transduction, cell differentiation, and sarcomere organization[1][5][7]. Knockdown studies in cardiac myocytes suggest that SBK2 is critical for sarcomere integrity and muscle differentiation, indicating importance in heart development and possibly disease[7]. Although annotated in major gene/protein databases, its biological roles are still being clarified and it is not currently a direct therapeutic target of any approved drugs[1][5][7].
- Other names
- Serine/threonine-protein kinase SBK2SGK069SgK069Sugen kinase 69SH3-binding domain kinase family, member 2
02
Mechanism of action
Not established for clinical drugs; mechanism would be expected to involve inhibition or modulation of serine/threonine kinase activity if targeted
03
Biological functions
Sarcomere organization and integrity (cardiac muscle)Regulation of cardiomyocyte differentiationInvolved in MAPK (mitogen-activated protein kinase) cascadeTransferase activity, transferring phosphorus-containing groupsProtein phosphorylation, signal transductionPossible roles in chromatin modification, cytoskeletal organization, intracellular trafficking, and translation (putative based on proteomic interaction studies)
04
Disease associations
Cardiac muscle development and sarcomere-related disordersPotential implication in heart disease (based on its role in sarcomere integrity; specific disease associations are emerging but not yet well-defined)Other roles are not yet clearly established
05
Safety considerations
None documented for therapeutic targeting, as no drugs currently target SBK2 directlyGiven its muscle specificity and role in sarcomere integrity, targeting could pose risk for cardiac muscle function
06
Biomarkers
Potential candidate for cardiac muscle differentiation and sarcomere organization biomarkers (research context, not clinically validated)
Beyond the preview
Go deeper on SH3 domain binding kinase family member 2 (SBK2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SH3 domain binding kinase family member 2 (SBK2).